NCT07066722

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

A Phase 1, Open-Label Study to Evaluate the Relative Bioavailability and the Effect of Food on VH4524184 Tablet Formulations, and to Evaluate the Potential for VH4524184 Drug-Drug-Interactions in Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 126 (actual)
• Sponsor: ViiV Healthcare · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The aim of the study is to gather information on how the drug behaves in healthy adults, how it is absorbed, and how it interacts when taken with other medicines.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	VH4524184	VH4524184 will be administered.
DRUG	Itraconazole	Itraconazole will be administered.
DRUG	Rifabutin	Rifabutin will be administered.
DRUG	Phenytoin	Extended phenytoin sodium will be administered.
DRUG	Metformin	Metformin will be administered.
DRUG	Digoxin	Digoxin will be administered.

Timeline

• Start date: 2025-07-07
• Primary completion: 2025-12-17
• Completion: 2025-12-17
• First posted: 2025-07-15
• Last updated: 2026-03-09

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study